Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q2 2021 · 10-Q
Revenue—
Net Income-$908.29K-$908.29KN/M vs Q2 2020 EPS Diluted-$0.04-$0.04N/M vs Q2 2020 Operating Income-$3,363,011N/M Operating Cash Flowderived-$2,021,877N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Aug 13, 2021 · 44 d after period end